BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Chinese Patent Office
Julphar
Cerilliant
Dow
Queensland Health
Accenture
McKesson
Teva
Cantor Fitzgerald

Generated: January 16, 2018

DrugPatentWatch Database Preview

Leo Labs Company Profile

« Back to Dashboard

What is the competitive landscape for LEO LABS, and what generic alternatives to LEO LABS drugs are available?

LEO LABS has one approved drug.

There are twelve US patents protecting LEO LABS drugs on LEO LABS drugs in the past three years.

There are forty-eight patent family members on LEO LABS drugs in twenty-four countries and fourteen supplementary protection certificates in ten countries.

Summary for Leo Labs
International Patents:48
US Patents:12
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Leo Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LEO LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 0.05% ➤ Subscribe 1/27/2016

Non-Orange Book US Patents for Leo Labs

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,603,822 Therapeutic compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Leo Labs Drugs

Supplementary Protection Certificates for Leo Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
185 Luxembourg ➤ Subscribe PRODUCT NAME: INGENANE OU UN DERIVE(SEL OU ESTER)DE CELUI-CI
1015413/01 Switzerland ➤ Subscribe PRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013
2014 00042 Denmark ➤ Subscribe PRODUCT NAME: INGENOLMEBUTAT ELLER ET DERIVAT (SALT ELLER ESTER) DERAF); REG. NO/DATE: EU/1/12/796/001-002 20121115
0682 Netherlands ➤ Subscribe PRODUCT NAME: INGENOLMEBUTAAT OF EEN DERIVAAT (ZOUT OF ESTER) DAARVAN; REGISTRATION NO/DATE: EU/1/12/796 20121119
00592 Netherlands ➤ Subscribe PRODUCT NAME: INGENAN OF EEN DERIVAAT (ZOUT OF ESTER) DAARVAN; REGISTRATION NO/DATE: EU/1/12/796/001-002 20121115
2014030 Lithuania ➤ Subscribe PRODUCT NAME: INGENOLI MEBUTATUM; REGISTRATION NO/DATE: EU/1/'12/796/001, 2012 11 15 EU/1/12/796/002 20121115
2013 00024 Denmark ➤ Subscribe
5 Finland ➤ Subscribe
0140025 00111 Estonia ➤ Subscribe PRODUCT NAME: INGENOOLMEBUTAAT;REG NO/DATE: K(2012)8481 (LOPLIK) 19.11.2012
1988877/01 Switzerland ➤ Subscribe PRODUCT NAME: INGENOLMEBUTAT; REGISTRATION NO/DATE: SWISSMEDIC 62763 12.06.2013
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
AstraZeneca
Queensland Health
Johnson and Johnson
Baxter
Daiichi Sankyo
Cantor Fitzgerald
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot